GLMD Fundamental Analysis - GALMED PHARMACEUTICALS LTD

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GLMD. GLMD was compared to 556 industry peers in the Biotechnology industry. While GLMD seems to be doing ok healthwise, there are quite some concerns on its profitability. GLMD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

GLMD had negative earnings in the past year.

In the past year GLMD has reported a negative cash flow from operations.

In the past 5 years GLMD always reported negative net income.

In the past 5 years GLMD always reported negative operating cash flow.

1.2 Ratios

GLMD has a Return On Assets (-39.32%) which is in line with its industry peers.

GLMD's Return On Equity of -43.53% is fine compared to the rest of the industry. GLMD outperforms 68.17% of its industry peers.

		Industry Rank	Sector Rank
ROA	-39.32%
ROE	-43.53%
ROIC	N/A

ROA(3y)-63.37%

ROA(5y)-66.75%

ROE(3y)-76.34%

ROE(5y)-80.13%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLMD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLMD has more shares outstanding

Compared to 5 years ago, GLMD has more shares outstanding

GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -13.85, we must say that GLMD is in the distress zone and has some risk of bankruptcy.

GLMD has a worse Altman-Z score (-13.85) than 78.96% of its industry peers.

GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-13.85

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 9.02 indicates that GLMD has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 9.02, GLMD is in the better half of the industry, outperforming 74.28% of the companies in the same industry.

GLMD has a Quick Ratio of 9.02. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.

GLMD has a better Quick ratio (9.02) than 74.28% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.02
Quick Ratio	9.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.15% over the past year.

EPS 1Y (TTM)66.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%77.85%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLMD will show a very strong growth in Earnings Per Share. The EPS will grow by 20.74% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-152.71%

EPS Next 2Y15.81%

EPS Next 3Y17.45%

EPS Next 5Y20.74%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLMD. In the last year negative earnings were reported.

Also next year GLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

GLMD's earnings are expected to grow with 17.45% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.81%

EPS Next 3Y17.45%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLMD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (7/24/2025, 12:04:59 PM)

1.99

+0.12 (+6.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-22 2025-05-22/bmo

Earnings (Next)07-31 2025-07-31

Inst Owners2.55%

Inst Owner Change0.04%

Ins Owners2.9%

Ins Owner ChangeN/A

Market Cap4.50M

Analysts43.33

Price Target12.24 (515.08%)

Short Float %4.17%

Short Ratio0.1

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.27
P/tB	0.27
EV/EBITDA	N/A

EPS(TTM)-7.07

EYN/A

EPS(NY)-0.87

Fwd EYN/A

FCF(TTM)-2.31

FCFYN/A

OCF(TTM)-2.31

OCFYN/A

SpS0

BVpS7.47

TBVpS7.47

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-39.32%
ROE	-43.53%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-63.37%

ROA(5y)-66.75%

ROE(3y)-76.34%

ROE(5y)-80.13%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	9.02
Quick Ratio	9.02
Altman-Z	-13.85

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)66.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%77.85%

EPS Next Y-152.71%

EPS Next 2Y15.81%

EPS Next 3Y17.45%

EPS Next 5Y20.74%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y10.89%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y64.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y64.63%

OCF growth 3YN/A

OCF growth 5YN/A

GALMED PHARMACEUTICALS LTD (GLMD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens